ArticleInvestigational new drugs2024

A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors.

Noboru Yamamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.